CHRONIC SPONTANEOUS URTICARIA

This early-stage study tests a single dose of a new drug called LP-003 in 12 healthy adults to see if it is safe and how the body processes it. The drug is designed to help control chronic spontaneous urticaria (long-term hives). Participants are healthy volunteers aged 18 to 50.…

This study tests a new daily pill called remibrutinib for adults with chronic spontaneous urticaria (long-term hives and itching) that antihistamines don't control well. About 470 participants will receive either remibrutinib, a placebo, or an active control (omalizumab injection…

This study tests a new medication (omalizumab α) against the approved drug Xolair for people with long-term hives that don't get better with antihistamines. About 392 adults aged 15 to 75 took part. The main goal was to see how well the new drug reduces itching over 12 weeks.

This study looks at the long-term safety and effectiveness of remibrutinib, an experimental drug, for adults with chronic spontaneous urticaria (CSU) — a condition causing frequent hives and itching without a clear trigger. Participants are people who already completed earlier ph…

This study tests a new drug called barzolvolimab for people with chronic spontaneous urticaria (long-term hives and itching) that antihistamines don't control. About 963 adults will receive either the drug or a placebo to see if it reduces hives and itching over 12 weeks. The goa…

This study tested whether the drug ritlecitinib can safely control chronic spontaneous urticaria (CSU) — hives and itching lasting over six weeks. The trial planned to enroll adults aged 18–65 who would take the drug daily for 12 weeks and track their symptoms. However, the study…

This study tests a new drug called EVO756 in 160 adults with moderate to severe chronic hives that don't get better with standard allergy medicines. Participants will receive either EVO756 or a placebo to see if the drug reduces itching and hives. The goal is to find a safe and e…

This early-stage study tests a new drug, BGB-16673, in adults with chronic spontaneous urticaria (long-lasting hives with no clear trigger). The main goal is to check safety and how the drug moves through the body. About 34 participants will receive either the drug or a placebo, …

This study tests an experimental drug called barzolvolimab in about 976 adults with chronic spontaneous urticaria (CSU) — a condition causing daily hives and itching for at least 6 months. Participants must still have symptoms despite taking standard antihistamines. The study com…

This study tests an experimental drug called briquilimab in adults with chronic spontaneous urticaria (CSU) — long-lasting hives and itching that don't get better with usual antihistamines or the drug omalizumab. The trial has three parts, with some participants receiving the dru…

This study is creating a large registry of 15,000 adults and children with inflammatory skin conditions like eczema, psoriasis, and vitiligo. Researchers will follow participants in regular clinics to see how well current and new treatments work and what side effects occur. The g…